Joel Palefsky, MD

Headshot of Joel Palefsky
User Profile Photo

Joel Palefsky, MD

User Profile Name
Member, CFAR Scientific Council
Professor, School of Medicine
User Profile Title
User Profile Email
Visit CTSI Profile

Biography

Joel Palefsky, M.D., C.M., F.R.C.P.(C). Professor of Medicine and Infectious Diseases at the University of California San Francisco School of Medicine. He is an internationally recognized expert on the molecular biology, treatment, pathogenesis and natural history of anogenital human papillomavirus infections, particularly in the setting of HIV infection. He is the director of the world's first clinic devoted to prevention of anal cancer, the Anal Neoplasia Clinic Research and Education Center at the UCSF Cancer Center. He is the vice-chair of the National Cancer Institute (NCI)-supported AIDS Malignancy Consortium. He is the chair of the Anal Cancer /HSIL Outcomes Research (ANCHOR) Study, a national multi-site NIH study designed to determine whether treatment of anal cancer precursor lesions prevents the development of anal cancer and to identify biomarkers of progression. He is founder and past president of the International Anal Neoplasia Society and is past president of the International Papillomavirus Society. He is the founder and chairperson of the IPVS International HPV Awareness Campaign.
CTSI Profile Bio

Displaying 51 - 75 of 366

  1. Colie C, Michel KG, Massad LS, Wang C, D'Souza G, Rahangdale L, Flowers L, Milam J, Palefsky JM, Minkoff H, Strickler HD, Kassaye SG. Natural History of Cervical Intraepithelial Neoplasia-2 in HIV-Positive Women of Reproductive Age. J Acquir Immune Defic Syndr. 2018 12 15; 79(5):573-579.
    http://www.ncbi.nlm.nih.gov/pubmed/30272635
  2. Keller MJ, Burk RD, Massad LS, Eltoum IE, Hessol NA, Anastos K, Xie X, Minkoff H, Xue X, Reimers LL, Kuniholm M, D'Souza G, Colie C, Aouizerat B, Palefsky JM, Strickler HD. Racial differences in human papilloma virus types amongst United States women with HIV and cervical precancer. AIDS. 2018 11 28; 32(18):2821-2826.
    http://www.ncbi.nlm.nih.gov/pubmed/30234608
  3. Chinyowa S, Palefsky JM, Chirenje ZM, Makunike-Mutasa R, Munjoma M, Muguti GI. Anal human papillomavirus infection in HIV-positive men and women at two opportunistic infections clinics in Harare, Zimbabwe. BMC Public Health. 2018 Nov 14; 18(1):1260.
    http://www.ncbi.nlm.nih.gov/pubmed/30428859
  4. Samwel K, Kahesa C, Mwaiselage J, Gonzalez D, West JT, Wood C, Palefsky J, Angeletti PC. Analytical performance of a low-cost multiplex polymerase chain reaction human papillomavirus genotyping assay for use in Sub-Saharan Africa. J Med Virol. 2019 02; 91(2):308-316.
    http://www.ncbi.nlm.nih.gov/pubmed/30281790
  5. Gradissimo A, Lam J, Attonito JD, Palefsky J, Massad LS, Xie X, Eltoum IE, Rahangdale L, Fischl MA, Anastos K, Minkoff H, Xue X, D'Souza G, Flowers LC, Colie C, Shrestha S, Hessol NA, Strickler HD, Burk RD. Methylation of High-Risk Human Papillomavirus Genomes Are Associated with Cervical Precancer in HIV-Positive Women. Cancer Epidemiol Biomarkers Prev. 2018 12; 27(12):1407-1415.
    http://www.ncbi.nlm.nih.gov/pubmed/30237251
  6. Burger EA, Dyer MA, Sy S, Palefsky JM, de Pokomandy A, Coutlee F, Silverberg MJ, Kim JJ. Development and Calibration of a Mathematical Model of Anal Carcinogenesis for High-Risk HIV-Infected Men. J Acquir Immune Defic Syndr. 2018 09 01; 79(1):10-19.
    http://www.ncbi.nlm.nih.gov/pubmed/29757775
  7. Mudini W, Palefsky JM, Hale MJ, Chirenje MZ, Makunike-Mutasa R, Mutisi F, Murahwa A, Mario A. Human Papillomavirus Genotypes in Invasive Cervical Carcinoma in HIV-Seropositive and HIV-Seronegative Women in Zimbabwe. J Acquir Immune Defic Syndr. 2018 09 01; 79(1):e1-e6.
    http://www.ncbi.nlm.nih.gov/pubmed/29781877
  8. Wechsler EI, Tugizov S, Herrera R, Costa MD, Palefsky JM. Erratum: E5 can be expressed in anal cancer and leads to epidermal growth factor receptor-induced invasion in a human papillomavirus 16-transformed anal epithelial cell line. J Gen Virol. 2018 07; 99(7):948.
    http://www.ncbi.nlm.nih.gov/pubmed/29966543
  9. Kahn JA, Lee J, Belzer M, Palefsky JM. HIV-Infected Young Men Demonstrate Appropriate Risk Perceptions and Beliefs about Safer Sexual Behaviors after Human Papillomavirus Vaccination. AIDS Behav. 2018 Jun; 22(6):1826-1834.
    http://www.ncbi.nlm.nih.gov/pubmed/28220313
  10. Ellsworth GB, Lensing SY, Ogilvie CB, Lee JY, Goldstone SE, Berry-Lawhorn JM, Jay N, Stier EA, Logan JS, Einstein MH, Saah A, Mitsuyasu RT, Aboulafia D, Palefsky JM, Wilkin TJ. A delayed dose of quadrivalent human papillomavirus vaccine demonstrates immune memory in HIV-1-infected men. Papillomavirus Res. 2018 12; 6:11-14.
    http://www.ncbi.nlm.nih.gov/pubmed/29807211
  11. Kojic EM, Conley L, Bush T, Cu-Uvin S, Unger ER, Henry K, Hammer J, Escota G, Darragh TM, Palefsky JM, Brooks JT, Patel P. Prevalence and Incidence of Anal and Cervical High-Risk Human Papillomavirus (HPV) Types Covered by Current HPV Vaccines Among HIV-Infected Women in the SUN Study. J Infect Dis. 2018 04 23; 217(10):1544-1552.
    http://www.ncbi.nlm.nih.gov/pubmed/29452366
  12. Burkhalter JE, Atkinson TM, Berry-Lawhorn J, Goldstone S, Einstein MH, Wilkin TJ, Lee J, Cella D, Palefsky JM. Initial Development and Content Validation of a Health-Related Symptom Index for Persons either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions. Value Health. 2018 08; 21(8):984-992.
    http://www.ncbi.nlm.nih.gov/pubmed/30098677
  13. Wechsler EI, Tugizov S, Herrera R, Da Costa M, Palefsky JM. E5 can be expressed in anal cancer and leads to epidermal growth factor receptor-induced invasion in a human papillomavirus 16-transformed anal epithelial cell line. J Gen Virol. 2018 05; 99(5):631-644.
    http://www.ncbi.nlm.nih.gov/pubmed/29624161
  14. Ortiz AP, González D, Vivaldi-Oliver J, Castañeda M, Rivera V, Díaz E, Centeno H, Muñoz C, Palefsky J, Joshipura K, Pérez CM. Periodontitis and oral human papillomavirus infection among Hispanic adults. Papillomavirus Res. 2018 06; 5:128-133.
    http://www.ncbi.nlm.nih.gov/pubmed/29555599
  15. Ortiz AP, Tortolero-Luna G, Romaguera J, Pérez CM, González D, Muñoz C, González L, Marrero E, Suárez E, Palefsky JM, Panicker G, Unger ER. Seroprevalence of HPV 6, 11, 16 and 18 and correlates of exposure in unvaccinated women aged 16-64 years in Puerto Rico. Papillomavirus Res. 2018 06; 5:109-113.
    http://www.ncbi.nlm.nih.gov/pubmed/29555601
  16. Patel P, Bush T, Kojic EM, Conley L, Unger ER, Darragh TM, Henry K, Hammer J, Escota G, Palefsky JM, Brooks JT. Prevalence, Incidence, and Clearance of Anal High-Risk Human Papillomavirus Infection Among HIV-Infected Men in the SUN Study. J Infect Dis. 2018 03 05; 217(6):953-963.
    http://www.ncbi.nlm.nih.gov/pubmed/29211874
  17. Somia IKA, Teeratakulpisarn N, Jeo WS, Yee IA, Pankam T, Nonenoy S, Trachuntong D, Mingkwanrungrueng P, Sukmawati MDD, Ramautarsing R, Nilasari H, Hairunisa N, Azwa I, Yunihastuti E, Merati TP, Phanuphak P, Palefsky J, Phanuphak N. Prevalence of and risk factors for anal high-risk HPV among HIV-negative and HIV-positive MSM and transgender women in three countries at South-East Asia. Medicine (Baltimore). 2018 Mar; 97(10):e9898.
    http://www.ncbi.nlm.nih.gov/pubmed/29517698
  18. Pérez-Caraballo AM, Suarez E, Unger ER, Palefsky JM, Panicker G, Ortiz AP. Seroprevalence of Human Papillomavirus (HPV) Type 6, 11, 16, 18, by Anatomic Site of HPV Infection, in Women Aged 16-64 Years living in the Metropolitan Area of San Juan, Puerto Rico. P R Health Sci J. 2018 03; 37(1):26-31.
    http://www.ncbi.nlm.nih.gov/pubmed/29547681
  19. Garland SM, Giuliano A, Brotherton J, Moscicki AB, Stanley M, Kaufmann AM, Bhatla N, Sankaranarayanan R, Palefsky JM, de Sanjose S. IPVS statement moving towards elimination of cervical cancer as a public health problem. Papillomavirus Res. 2018 06; 5:87-88.
    http://www.ncbi.nlm.nih.gov/pubmed/29499389
  20. Chen JS, Ma E, Harrington LB, Da Costa M, Tian X, Palefsky JM, Doudna JA. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science. 2018 04 27; 360(6387):436-439.
    http://www.ncbi.nlm.nih.gov/pubmed/29449511
  21. Williamson AL, Garland S, Palefsky J, Rybicki E, Stanley M, de Sanjosé S. The Cape Town declaration on human papillomavirus related disease. Papillomavirus Res. 2018 06; 5:59-60.
    http://www.ncbi.nlm.nih.gov/pubmed/29294358
  22. Dube Mandishora RS, Christiansen IK, Chin'ombe N, Duri K, Ngara B, Rounge TB, Meisal R, Ambur OH, Palefsky JM, Stray-Pedersen B, Chirenje ZM. Genotypic diversity of anogenital human papillomavirus in women attending cervical cancer screening in Harare, Zimbabwe. J Med Virol. 2017 09; 89(9):1671-1677.
    http://www.ncbi.nlm.nih.gov/pubmed/28390142
  23. Garland SM, Brotherton JML, Moscicki AB, Kaufmann AM, Stanley M, Bhatla N, Sankaranarayanan R, de Sanjosé S, Palefsky JM. HPV vaccination of immunocompromised hosts. Papillomavirus Res. 2017 12; 4:35-38.
    http://www.ncbi.nlm.nih.gov/pubmed/29179867
  24. Robbins HA, Strickler HD, Massad LS, Pierce CB, Darragh TM, Minkoff H, Keller MJ, Fischl M, Palefsky J, Flowers L, Rahangdale L, Milam J, Shrestha S, Colie C, D'Souza G. Cervical cancer screening intervals and management for women living with HIV: a risk benchmarking approach. AIDS. 2017 04 24; 31(7):1035-1044.
    http://www.ncbi.nlm.nih.gov/pubmed/28323758
  25. Raghavendran A, Hernandez AL, Lensing S, Gnanamony M, Karthik R, Sivasubramanian M, Kannangai R, Abraham P, Mathai D, Palefsky JM. Genital Human Papillomavirus Infection in Indian HIV-Seropositive Men Who Have Sex With Men. Sex Transm Dis. 2017 03; 44(3):173-180.
    http://www.ncbi.nlm.nih.gov/pubmed/28178116